- Home
- VRAR vs CLDI Comparison
VRAR vs CLDI Comparison
Compare VRAR & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAR
- CLDI
- Stock Information
- Founded
- VRAR 2016
- CLDI 2014
- Country
- VRAR United States
- CLDI United States
- Employees
- VRAR N/A
- CLDI N/A
- Industry
- VRAR Retail: Computer Software & Peripheral Equipment
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRAR Technology
- CLDI Health Care
- Exchange
- VRAR Nasdaq
- CLDI Nasdaq
- Market Cap
- VRAR N/A
- CLDI 14.0M
- IPO Year
- VRAR 2021
- CLDI N/A
- Fundamental
- Price
- VRAR $1.14
- CLDI $0.48
- Analyst Decision
- VRAR Strong Buy
- CLDI Strong Buy
- Analyst Count
- VRAR 1
- CLDI 2
- Target Price
- VRAR $2.62
- CLDI $15.00
- AVG Volume (30 Days)
- VRAR 114.4K
- CLDI 387.2K
- Earning Date
- VRAR 05-14-2025
- CLDI 05-13-2025
- Dividend Yield
- VRAR N/A
- CLDI N/A
- EPS Growth
- VRAR N/A
- CLDI N/A
- EPS
- VRAR 0.86
- CLDI N/A
- Revenue
- VRAR $591,251,000.00
- CLDI N/A
- Revenue This Year
- VRAR N/A
- CLDI N/A
- Revenue Next Year
- VRAR $30.52
- CLDI N/A
- P/E Ratio
- VRAR N/A
- CLDI N/A
- Revenue Growth
- VRAR N/A
- CLDI N/A
- 52 Week Low
- VRAR $0.50
- CLDI $0.35
- 52 Week High
- VRAR $7.00
- CLDI $4.90
- Technical
- Relative Strength Index (RSI)
- VRAR 49.15
- CLDI 39.49
- Support Level
- VRAR $0.97
- CLDI $0.41
- Resistance Level
- VRAR $1.08
- CLDI $0.52
- Average True Range (ATR)
- VRAR 0.09
- CLDI 0.07
- MACD
- VRAR 0.03
- CLDI 0.02
- Stochastic Oscillator
- VRAR 69.23
- CLDI 66.50
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.